EP0939612A1 - Stannogluconate enthaltende orale zusammensetzungen - Google Patents
Stannogluconate enthaltende orale zusammensetzungenInfo
- Publication number
- EP0939612A1 EP0939612A1 EP97911712A EP97911712A EP0939612A1 EP 0939612 A1 EP0939612 A1 EP 0939612A1 EP 97911712 A EP97911712 A EP 97911712A EP 97911712 A EP97911712 A EP 97911712A EP 0939612 A1 EP0939612 A1 EP 0939612A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sodium
- compositions
- composition
- stannous
- gluconate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
Definitions
- the present invention relates to a method of preventing or controlling colds and similar maladies, such as flu, through the use of an oral composition containing stannous gluconate applied to the gingival or oral mucosal tissue of the subject susceptible to colds.
- the common cold although not usually a serious illness, is a highly prevalent, discomforting and annoying infliction.
- the term "common cold” is applied to minor respiratory illnesses caused by a variety of different respiratory viruses. While rhinoviruses are the major known cause of common colds, accounting for approximately 30 percent of colds in adults, viruses in several other groups are also important. While immune responses occur, and infection with some respiratory tract viruses therefore could be prevented by a vaccine, development of a polytypic vaccine to cover all possible agents is impractical. Thus, the problem of controlling acute upper respiratory disease presents complex challenges, and the long-desired discovery of a single cure for the common cold is an unrealistic expectation.
- compositions for treatment of nasal and other cold, flu, allergy and sinus symptoms and the discomfort, pain, fever and general malaise associated therewith generally contain an analgesic (aspirin or acetaminophen) and one or more antihistamines, decongestants, cough suppressants, antitussives and expectorants.
- analgesic aspirin or acetaminophen
- Other specific pharmaceutical actives for nasal symptoms e.g., congestion
- These actives are generally delivered topically to the nasal mucosa via a nasal spray.
- oral drugs such as decongestants could pose a risk of unfavorable drug interactions and may cause an adverse reaction. It would, therefore, be highly desirable to deliver relief from specific nasal symptoms via compositions without the need for such pharmaceutical actives.
- the present invention relates to a method of reducing colds and cold-like symptoms, such as flu, in subjects susceptible to such maladies by applying a composition containing an effective amount of stannous gluconate to the gingival or oral mucosal tissues.
- compositions of the present invention contain certain essential components as well as non-essential components.
- Stannous gluconate is an essential component of the present compositions.
- This material is a known stannous chelate and may be provided to the present compositions as the chelate or as separate soluble stannous and gluconate salts and the chelate formed in-situ.
- Such salts include stannous chloride and sodium gluconate.
- Stannous gluconate is present in the present compositions at a level of from about 0.1% to about 11%, preferably from about 0.2% to about 4%.
- Acceptable Carrier is an essential component of the present compositions.
- the carrier for the active component(s) can be any vehicle suitable for use in the oral cavity.
- Such carriers include the usual components of mouthwashes, gargles, toothpastes, tooth powders, prophylaxis pastes, lozenges, gums and the like and are more fully described hereinafter. Dentifrices and mouthwashes are the preferred systems.
- the present compositions may contain antiplaque/gingivitis agents such as quaternary ammonium compounds, water insoluble agents such as triclosan, teas, as defined herein later, stannous salts and zinc salts.
- antiplaque/gingivitis agents such as quaternary ammonium compounds, water insoluble agents such as triclosan, teas, as defined herein later, stannous salts and zinc salts.
- the abrasive polishing material contemplated for use in the present invention can be any material which does not excessively abrade dentin.
- silicas including gels and precipitates, calcium carbonate, dicalcium orthophosphate dihydrate, calcium pyrophosphate, tricalcium phosphate, calcium polymetaphosphate, insoluble sodium polymetaphosphate, hydrated alumina, and resinous abrasive materials such as particulate condensation products of urea and formaldehyde, and other such as disclosed by Cooley et al. in U.S. Patent 3,070,510, December 25, 1962, incorporated herein by reference. Mixtures of abrasives may also be used.
- Silica dental abrasives of various types, can provide the unique benefits of exceptional dental cleaning and polishing performance without unduly abrading tooth enamel or dentin.
- Silica abrasive materials are also exceptionally compatible with sources of soluble fluoride and polyphosphonates. For these reasons they are preferred for use herein.
- the silica abrasive can be precipitated silica or silica gels such as the silica xerogels described in Pader et al., U.S. Patent No. 3,538,230, issued March 2, 1970 and DiGiulio, U.S. Patent No. 3,862,307, June 21, 1975, both incorporated herein by reference.
- Preferred precipitated silica materials include those marketed by the J. M. Huber Co ⁇ oration under the tradename, "Zeodent", particularly the silica carrying the designation "Zeodent 119". These silica abrasives are described in U.S. Patent No. 4,340,583, July 29, 1982, inco ⁇ orated herein by reference.
- the abrasive in the compositions described herein is present at a level of from about 6% to about 70%, preferably from about 15% to about 25% when the dentifrice is a toothpaste. Higher levels, as high as 90%, may be used if the composition is a toothpowder.
- compositions of the present invention may also contain a soluble fluoride ion source such as sodium, potassium, lithium fluorides, stannous fluoride, and sodium monofluorophosphate among many others.
- a soluble fluoride ion source such as sodium, potassium, lithium fluorides, stannous fluoride, and sodium monofluorophosphate among many others.
- the fluoride source should be sufficient to provide from about 50 to about 3500 ppm fluoride in a toothpaste or mouthrinse.
- Flavoring agents can also be added to dentifrice compositions. Suitable flavoring agents include, among many others, oil of wintergreen, oil of peppermint, oil of spearmint, and oil of clove. Sweetening agents which can be used include aspartame, acesulfame, saccharin, dextrose, levulose and sodium cyclamate. Flavoring and sweetening agents are generally used in dentifrices at levels of from about 0.005% to about 2% by weight.
- Dentifrice compositions can also contain emulsifying agents. Suitable emulsifying agents are those which are reasonably stable and foam throughout a wide pH range, including nonsoap anionic, nonionic, cationic, zwitterionic and amphoteric organic synthetic detergents. Many of these suitable surfactants are disclosed by Gieske et al. in U.S. Patent No. 4,051,234, September 27, 1977, inco ⁇ orated herein in its entirety by reference.
- Water is also present in the toothpastes of this invention.
- Water employed in the preparation of commercially suitable toothpastes should preferably be deionized and free of organic impurities.
- Water generally comprises from about 10% to 50%, preferably from about 20% to 40%, by weight of the toothpaste compositions herein. These amounts of water include the free water which is added plus that which is introduced with other materials such as with sorbitol.
- thickening agents are carboxyvinyl polymers of the type mentioned previously herein, xanthan gum, carrageenan, hydroxyethyl cellulose and water soluble salts of cellulose ethers such as sodium carboxymethyl cellulose and sodium carboxymethyl hydroxyethyl cellulose.
- Natural gums such as gum karaya, gum arabic, and gum tragacanth can also be used.
- Colloidal magnesium aluminum silicate or finely divided silica can be used as part of the thickening agent to further improve texture.
- Thickening agents in an amount from 0.5% to 5.0% by weight of the total composition can be used.
- humectant material in a toothpaste to keep it from hardening.
- Suitable humectants include glycerin, sorbitol, xylitol, and other edible polyhydric alcohols at a level of from about 5% to about 70%.
- Mouthwash composition is a mouthwash composition.
- Conventional mouthwash composition components can comprise the carrier for the active agents of the present invention.
- Mouthwashes generally comprise from about 20:1 to about 2: 1 of a water/ethyl alcohol solution and preferably other ingredients such as flavor, sweeteners, humectants and sudsing agents such as those mentioned above for dentifrices.
- the humectants, such as glycerin and sorbitol give a moist feel to the mouth.
- the mouthwashes of the invention comprise 0% to 60% (preferably 10% to 25%) ethyl alcohol, 0% to 20% (preferably 5% to 20%) of a humectant, 0% to 2% (preferably 0.01% to 0.15%) emulsifying agent, 0% to 0.5% (preferably 0.005% to 0.06%) sweetening agent such as saccharin, 0% to 0.3% (preferably 0.03% to 0.3%) flavoring agent, and the balance water.
- Suitable lozenge and chewing gum components are disclosed in U.S. Patent No. 4,083,955, April 11, 1978 to Grabenstetter et al., inco ⁇ orated herein by reference.
- pyrophosphate salts such as those described in U.S. 4,515,772, May 7, 1985 to Parran et al. inco ⁇ orated herein by reference.
- nonionic antimicrobials such as triclosan described in U.S. 4,894,220, January 16, 1990 to Nabi et al. Both patents are inco ⁇ orated herein by reference.
- alkali metal bicarbonate such as sodium bicarbonate.
- alkali metal bicarbonate such as sodium bicarbonate.
- compositions of the subject invention are controlled-release drug delivery systems for placement in the periodontal pocket.
- Such systems include, but are not limited to, the cellulose hollow fibers disclosed in U.S. Pat. No. 4,175,326, issued to Goodson on Nov. 27, 1979; the ethylcellulose films disclosed in U.S. Pat. No. 4,568,535 issued to Loesche on Feb. 4, 1986; the absorbable putty-like material disclosed in U.S. Pat. No. 4,568,536 issued to Kronenthal, Maftei and Levy on Feb. 4, 1986; the biodegradable microspheres and matrix disclosed in U.S. Pat. No. 4,685,883 issued to Jernberg on Aug.
- Such controlled-release delivery systems generally include a solid matrix, usually of polymeric material, loaded with one or more active agents, the matrix entrapping stannous gluconate. Typically, the active agents diffuse from the solid material into the periodontal pocket over time.
- Preferred controlled-release drug delivery systems comprise from about 0.001% to about 50%, more preferably from about 0.01% to about 25%, more preferably still from about 0.1% to about 15%, still more preferably from about 1% to about 10%, of stannous gluconate and a controlled-release carrier.
- the pH of the present compositions and/or its pH in the mouth can be any pH which is safe for the mouth's hard and soft tissues.
- Such pH*s are generally from about 3 to about 10, preferably from about 5 to about 9.
- the carrier compositions of the present invention can be made using methods which are common in the oral products area.
- toothpaste compositions may be prepared by mixing part of the humectant and water together and heating to 66°-71°C.
- the fluoride source if present, is then added along with the sweetener, the opacifier and the flavor.
- the present invention in its method aspect involves applying to the gingival and/or oral mucosal tissue safe and effective amounts of the compositions. Generally an amount of at least about 5 grams of a mouthwash and at least about 0.5 of a toothpaste or liquid dentifrice.
- a preferred method of the subject invention involves the contact of a composition of the subject invention with oral cavity soft tissue for at least about 15 seconds, preferably from about 20 seconds to about 10 minutes, more preferably from about 30 seconds to about 60 seconds.
- the method often involves expectoration of most of the composition following such contact, preferably followed by rinsing, e.g., with water.
- the frequency of such contact is preferably from about once per week to about five times per day, more preferably from about thrice per week to about four times per day, more preferably still from about once per day to about thrice per day.
- the period of such treatment typically ranges from about one day to a lifetime.
- people may recognize that they will be exposed to a cold's virus and they then can use the products described herein either prior to the exposure, following exposure, or at the first signs of a cold.
- compositions used in the present method may also be used by the subject as a gargle. Additionally, subjects taking significant doses of Vitamin C may achieve an enhanced colds benefit through the use of the compositions described herein.
- Titanium Dioxide 0.525 0.525
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73529096A | 1996-10-22 | 1996-10-22 | |
US735290 | 1996-10-22 | ||
PCT/US1997/018508 WO1998017237A1 (en) | 1996-10-22 | 1997-10-14 | Oral compositions containing stannous gluconate |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0939612A1 true EP0939612A1 (de) | 1999-09-08 |
Family
ID=24955163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97911712A Withdrawn EP0939612A1 (de) | 1996-10-22 | 1997-10-14 | Stannogluconate enthaltende orale zusammensetzungen |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0939612A1 (de) |
KR (1) | KR20000052736A (de) |
CN (1) | CN1238673A (de) |
AU (1) | AU722452B2 (de) |
BR (1) | BR9712993A (de) |
CA (1) | CA2269473A1 (de) |
WO (1) | WO1998017237A1 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010013377A (ko) | 1997-06-04 | 2001-02-26 | 데이비드 엠 모이어 | 마일드한 잔류성 항균 조성물 |
US6846478B1 (en) | 1998-02-27 | 2005-01-25 | The Procter & Gamble Company | Promoting whole body health |
US6303104B1 (en) * | 1999-02-12 | 2001-10-16 | Enamelon, Inc. | Remineralizing/mineralizing oral products having improved whitening and stain removal properties |
US6436885B2 (en) | 2000-01-20 | 2002-08-20 | The Procter & Gamble Company | Antimicrobial cleansing compositions containing 2-pyrrolidone-5-carboxylic acid |
US6416981B1 (en) | 2000-05-23 | 2002-07-09 | Nec Partnership | Production of gluconate salts |
CN1536989A (zh) | 2000-06-30 | 2004-10-13 | 促进全身健康 | |
KR20030045530A (ko) * | 2001-12-04 | 2003-06-11 | 김명중 | 금박 치약 조성물 및 그 제조방법 |
WO2007099398A2 (en) * | 2005-09-27 | 2007-09-07 | Naturalite Benelux B.V. | Methods and compositions for treatment of skin |
NO339503B1 (no) * | 2014-06-18 | 2016-12-19 | Meda Otc Ab | Sammensetning for forebygging eller behandling av dental erosjon |
CN104930773B (zh) * | 2015-07-06 | 2017-06-06 | 珠海格力电器股份有限公司 | 电子膨胀阀的控制方法及装置和空调器 |
CA3008379C (en) * | 2015-12-30 | 2023-08-15 | Colgate-Palmolive Company | Oral care product and methods of use and manufacture thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB779504A (en) * | 1954-03-11 | 1957-07-24 | American Cyanamid Co | Tetracycline antibiotic complexes |
EP0311259A3 (de) * | 1987-09-14 | 1989-04-26 | The Procter & Gamble Company | Orale-Zusammensetzungen |
DE3852599T2 (de) * | 1987-09-14 | 1995-08-17 | Procter & Gamble | Orale Zusammensetzungen. |
US5004597A (en) * | 1987-09-14 | 1991-04-02 | The Procter & Gamble Company | Oral compositions comprising stannous flouride and stannous gluconate |
US5213790A (en) * | 1991-10-23 | 1993-05-25 | The Procter & Gamble Co. | Methods of reducing plaque and gingivitis with reduced staining |
US5281410A (en) * | 1991-10-23 | 1994-01-25 | The Proctor & Gamble Company | Methods of reducing plaque and gingivitis with reduced staining |
US5281411A (en) * | 1992-07-31 | 1994-01-25 | The Procter & Gamble Company | Oral compositions |
US5338537A (en) * | 1993-10-05 | 1994-08-16 | The Procter & Gamble Company | Oral compositions |
-
1997
- 1997-10-14 BR BR9712993-3A patent/BR9712993A/pt not_active IP Right Cessation
- 1997-10-14 KR KR1019990703536A patent/KR20000052736A/ko not_active Application Discontinuation
- 1997-10-14 AU AU49021/97A patent/AU722452B2/en not_active Ceased
- 1997-10-14 CA CA002269473A patent/CA2269473A1/en not_active Abandoned
- 1997-10-14 WO PCT/US1997/018508 patent/WO1998017237A1/en not_active Application Discontinuation
- 1997-10-14 CN CN97180028A patent/CN1238673A/zh active Pending
- 1997-10-14 EP EP97911712A patent/EP0939612A1/de not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO9817237A1 * |
Also Published As
Publication number | Publication date |
---|---|
BR9712993A (pt) | 2000-04-18 |
KR20000052736A (ko) | 2000-08-25 |
CA2269473A1 (en) | 1998-04-30 |
WO1998017237A1 (en) | 1998-04-30 |
CN1238673A (zh) | 1999-12-15 |
AU722452B2 (en) | 2000-08-03 |
AU4902197A (en) | 1998-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6235269B1 (en) | Oral care compositions comprising chlorite and methods | |
US6077502A (en) | Oral care compositions comprising chlorite and methods | |
EP0344701B1 (de) | Perorale Zusammensetzungen | |
US6251372B1 (en) | Oral care compositions comprising chlorite and methods | |
EP0652743B1 (de) | Präparate zur buccale verwendung | |
RU2455001C2 (ru) | Композиции и способы лечения ксеростомии | |
US5389360A (en) | Oral compositions | |
AU722452B2 (en) | Oral compositions containing stannous gluconate | |
EP0311260B1 (de) | Orale Zusammensetzungen | |
JPH02286613A (ja) | 新規組成物 | |
WO1998017270A1 (en) | Oral compositions containing zinc citrate salts | |
US5496539A (en) | Oral compositions | |
EP0954294A1 (de) | Verwendung von h2-antagonisten zur herstellung einer topischen zubereitung zur behandlung von erkrankungen | |
EP0311259A2 (de) | Orale-Zusammensetzungen | |
MXPA99003767A (en) | Oral compositions containing zinc citrate salts | |
MXPA99003764A (en) | Oral compositions containing stannous gluconate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990423 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20000118 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20010130 |